Industry Symposia
Industry Sponsored and Satellite CME Symposia are commercially supported educational and promotional activities held in conjunction with the IASLC 2024 World Conference on Lung Cancer. The programs are approved by the IASLC as an independent activity. These programs are not supported or endorsed by the IASLC and are not part of the official IASLC ACCME accredited program.
IS01: Join us to hear thought leaders discuss a newly approved combination therapy that includes RYBREVANT® (amivantamab-vmjw)
Room 20BC, San Diego Convention Center
Presented by Johnson & Johnson
IS02: Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Room 33ABC, San Diego Convention Center
Presented by Amgen
IS04: A Treatment Option for Certain Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)
Room 20D, San Diego Convention Center
Presented by Merck & Co., Inc.
IS07: Emerging Therapies in Clinical Practice: What Are the Patient Perspectives on the Future of Lung Cancer Treatment?
Room 30DE, San Diego Convention Center
Presented by Boehringer Ingelheim
IS08: New Treatment Approach for HER2+ (IHC3+) Metastatic Solid Tumors After Prior Systemic Treatment
Room 20A, San Diego Convention Center
Presented by Daiichi Sankyo and AstraZeneca
IS10: LORBRENA® (lorlatinib): Overview of CROWN Trial Efficacy and Safety Data
Room 20BC, San Diego Convention Center
Presented by Pfizer Oncology
IS11: Un-Met Needs in NSCLC: The Emerging Potential Role of ADCs Targeting c-Met
Room 33ABC, San Diego Convention Center
Presented by AbbVie
IS13: Accelerating Treatment Initiation with Next-Day NGS: Insights from a Multidisciplinary Collaboration Program in Precision Oncology
Room 33ABC, San Diego Convention Center
Presented by Thermo Fisher Scientific
IS16: Actionable Biomarkers in Early-Stage NSCLC
Room 33ABC, San Diego Convention Center
Presented by Roche Diagnostics